• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

作者信息

Vettor Roberto, Inzucchi Silvio E, Fioretto Paola

机构信息

Internal Medicine 3, Department of Medicine, University of Padua, via Giustiniani 2, 35128, Padova, Italy.

Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.

出版信息

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.

DOI:10.1007/s00125-016-4194-y
PMID:28074254
Abstract
摘要

相似文献

1
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.恩格列净对心血管系统的益处：依赖和不依赖SGLT2的作用。
Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.
2
The EMPA-REG study: What has it told us? A diabetologist's perspective.恩格列净心血管结局研究（EMPA-REG）：它告诉了我们什么？一位糖尿病专家的观点。
J Diabetes Complications. 2016 Jan-Feb;30(1):1-2. doi: 10.1016/j.jdiacomp.2015.10.013. Epub 2015 Oct 21.
3
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.吡格列酮的复兴：与钠-葡萄糖共转运蛋白 2 抑制剂联合应用的最佳药物。
Diabetes Obes Metab. 2016 May;18(5):454-62. doi: 10.1111/dom.12652. Epub 2016 Apr 6.
4
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂降低 2 型糖尿病（T2DM）患者心血管风险的潜力。
J Diabetes Complications. 2013 May-Jun;27(3):280-6. doi: 10.1016/j.jdiacomp.2012.12.004. Epub 2013 Feb 1.
5
EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.恩格列净心血管结局研究（EMPA-REG）：葡萄糖排泄和脂质动员——而非储存——挽救生命。
J Diabetes Complications. 2016 May-Jun;30(4):753. doi: 10.1016/j.jdiacomp.2016.02.015. Epub 2016 Feb 23.
6
EMPA-REG - the "diuretic hypothesis".恩格列净心血管结局研究（EMPA-REG）——“利尿剂假说”。
J Diabetes Complications. 2016 Jan-Feb;30(1):3-4. doi: 10.1016/j.jdiacomp.2015.10.012. Epub 2015 Oct 21.
7
[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].恩格列净：一种对心脏死亡率有确切积极作用的口服抗糖尿病药物
Praxis (Bern 1994). 2016 Mar 16;105(6):349-50. doi: 10.1024/1661-8157/a002288.
8
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.二肽基肽酶-4抑制剂与钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者血脂影响的比较
Lipids Health Dis. 2017 Apr 13;16(1):58. doi: 10.1186/s12944-017-0443-4.
9
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.达格列净与二肽基肽酶-4 抑制剂治疗相比，可降低 2 型糖尿病患者（CVD-REAL Nordic）发生心血管事件和全因死亡率的风险：一项多中心观察性研究。
Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8.
10
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.钠-葡萄糖协同转运蛋白2抑制剂对心血管的保护作用：潜在机制
Am J Med. 2017 Jun;130(6S):S30-S39. doi: 10.1016/j.amjmed.2017.04.009.

引用本文的文献

1
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）和胰高血糖素样肽-1受体激动剂（GLP-1Ra）的潜在机制及心脏保护作用：来自心血管磁共振成像的见解
Cardiovasc Diabetol. 2024 Mar 11;23(1):94. doi: 10.1186/s12933-024-02181-7.
2
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art.钠-葡萄糖协同转运蛋白2抑制剂与线粒体功能：现状
EXCLI J. 2023 Jan 4;22:53-66. doi: 10.17179/excli2022-5482. eCollection 2023.
3
Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.

本文引用的文献

1
Empagliflozin decreases myocardial cytoplasmic Na through inhibition of the cardiac Na/H exchanger in rats and rabbits.恩格列净通过抑制大鼠和兔子心脏中的钠/氢交换体来降低心肌细胞质中的钠含量。
Diabetologia. 2017 Mar;60(3):568-573. doi: 10.1007/s00125-016-4134-x. Epub 2016 Oct 17.
2
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病治疗中的应用：心血管和肾脏效应、潜在机制及临床应用
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
3
恩格列净通过抑制平滑肌细胞增殖和加速内皮再生来预防新生内膜形成。
Front Cardiovasc Med. 2022 Aug 9;9:956041. doi: 10.3389/fcvm.2022.956041. eCollection 2022.
4
Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.达格列净对心肌胰岛素敏感性和灌注的影响：DAPA - HEART试验的原理与设计
Diabetes Ther. 2021 Jul;12(7):2101-2113. doi: 10.1007/s13300-021-01083-1. Epub 2021 May 26.
5
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.钠-葡萄糖协同转运蛋白 2 抑制剂通过减少自噬对心肌梗死的心脏保护作用机制。
Protein Cell. 2022 May;13(5):336-359. doi: 10.1007/s13238-020-00809-4. Epub 2021 Jan 8.
6
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病。
Nat Rev Endocrinol. 2020 Oct;16(10):556-577. doi: 10.1038/s41574-020-0392-2. Epub 2020 Aug 27.
7
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.SGLT2抑制剂对阿霉素诱导的心力衰竭的心脏保护潜力
Korean Circ J. 2019 Dec;49(12):1183-1195. doi: 10.4070/kcj.2019.0180. Epub 2019 Jul 31.
8
Mitochondrial Dysfunction and Diabetes: Is Mitochondrial Transfer a Friend or Foe?线粒体功能障碍与糖尿病：线粒体转移是福是祸？
Biology (Basel). 2019 May 11;8(2):33. doi: 10.3390/biology8020033.
9
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净可减轻高血压性心力衰竭大鼠的心肌纤维化并改善心室血液动力学。
Cardiovasc Diabetol. 2019 Apr 1;18(1):45. doi: 10.1186/s12933-019-0849-6.
10
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.恩格列净可降低 2 型糖尿病患者的血压和尿酸：系统评价和荟萃分析。
J Hum Hypertens. 2019 Apr;33(4):327-339. doi: 10.1038/s41371-018-0134-2. Epub 2018 Nov 15.
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
在 EMPA-REG OUTCOME 试验中对 CV 进行保护：“节俭型底物”假说。
Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330.
4
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.能量代谢重编程能否解释 EMPA-REG OUTCOME 研究中有益的心脏肾脏结局？一个统一的假说。
Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.
5
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.钠-葡萄糖协同转运蛋白2抑制剂与心血管风险：依帕列净治疗对心血管结局影响的研究经验教训
Diabetes Care. 2016 May;39(5):717-25. doi: 10.2337/dc16-0041.
6
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.恩格列净治疗心血管高危2型糖尿病患者的心力衰竭结局：EMPA-REG OUTCOME®试验结果
Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.
7
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
8
Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport.由于钠-葡萄糖协同转运增强，糖尿病心脏中的细胞内钠离子浓度（[Na+]i）升高。
J Am Heart Assoc. 2015 Aug 27;4(9):e002183. doi: 10.1161/JAHA.115.002183.
9
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.2 型糖尿病患者对钠-葡萄糖共转运蛋白 2 抑制剂的代谢反应。
J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27.
10
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.达格列净可改善肌肉胰岛素敏感性，但会增强内源性葡萄糖生成。
J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27.